Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26745197 | 0.87 | DDB1 (0.31) | DDB1CRBNLMNAL3MBTL1 | |
| SCHEMBL24784048 | 0.87 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL22440137 | 0.86 | CA2 (0.33) | DDB1CRBNCYP19A1LMNA | |
| SCHEMBL24784108 | 0.86 | CHRNB2 (0.38) | CYP2D6 | |
| SCHEMBL24784047 | 0.84 | — | — | |
| SCHEMBL24784049 | 0.83 | KDM5A (0.32) | — | |
| SCHEMBL24784026 | 0.79 | — | — | |
| SCHEMBL24783326 | 0.79 | GSK3B (0.41) | DDB1CRBNLMNAL3MBTL1GSK3B | |
| SCHEMBL24784046 | 0.79 | — | — | |
| SCHEMBL24784109 | 0.78 | KDM5A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885CYP19A1 2650/4885 |
| US-11524949-B2 | Degraders and Degrons for targeted protein degradation | STUB1, MDM2, USP30 | DDB1 292/4885CRBN 37/4885CYP19A1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.